5-ASA Treatment for Ulcerative Colitis: What’s on the Horizon?

5-ASA Treatment for Ulcerative Colitis: What’s on the Horizon?

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis

Objective(s): This study is aimed to design and synthesize a prodrug of 5-aminosalicylic acid and evaluate its ameliorative effect on experimental ulcerative colitis (UC).Materials and Methods: 5-Aminosalicylic acid-alanine (5-ASA-ALA) was synthesized and characterized. Its stability study was conducted in rat plasma and in the gastroint...

Economic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis

The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.

5-Aminosalicylic acid (5-ASA), the active moiety of sulphasalazine (SASP), was given as a rectal enema to patients with mild to moderate distal ulcerative colitis to determine the minimum effective dosage. A double blind study was carried out using enemas containing 1, 2, or 4 g or 5-ASA or placebo for a one month treatment period. One hundred and thirteen patients with ulcerative colitis atten...

New 5-ASA Formulations for the Treatment of Ulcerative Colit is: A Review of Recent Data and Future Directions in Therapy

Mesalamine (5-aminosalicylic acid; 5-ASA) is the current, standard first-line therapy for the treatment of mild-tomoderate ulcerative colitis. 5-ASA acts topically, and therefore much effort has focused on the development of orally available 5-ASA formulations with the goals of maximizing the amount of drug delivered to sites of active inflammation within the intestine. However, differences in ...